Drug Database
Back to search

Netherlands· NL-9d453e9f2dd0

Enspryng 120 mg, oplossing voor injectie in voorgevulde spuit

A satralizumab product containing satralizumab, registered in Netherlands by Roche Registration GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC L04AC19

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEnspryng 120 mg, oplossing voor injec…ATCL04AC19REGISTER NO.NL-9d453e9f2dd0PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about satralizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Satralizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC19 (satralizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search satralizumab products by name

Satralizumab · ATC L04AC19

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
SATRALIZUMAB
Manufacturer
Roche Registration GmbH
Country
Netherlands (NL)
ATC code
L04AC19
ATC class
Satralizumab
Defined daily dose
4.3 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/21/1559

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

115 interactions on record for satralizumab.

Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check satralizumab against other medicinesHow interaction checks work

Satralizumab · interactions on record

115 records

  • 35 severe
  • 74 moderate
  • 6 minor

Most severe, free to view

  • CladribineL01BB04severe
  • RituximabL01FA01severe
  • RituximabL01XC02severe
  • Talimogene laherparepvecL01XL02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Satralizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All satralizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Enspryng, Enspryng Pre-Filled Pen Pre-Filled Pen
  • Liechtenstein · Enspryng, Enspryng Pre-Filled Pen Pre-Filled Pen
  • Norway · Enspryng, Enspryng Pre-Filled Pen Pre-Filled Pen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/281b9624-c3e8-48d6-bb1a-b4e68478ea37
GET /v1/drugs/281b9624-c3e8-48d6-bb1a-b4e68478ea37?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/enspryng-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Satralizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125528",
  "excipients": [
    "ARGININE, (L-)",
    "ASPARAGINEZUUR, (L-)",
    "HISTIDINE, (L-)",
    "POLOXAMEER 188",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "SATRALIZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2021/06/24",
  "procedure_number": "EMEA/H/C/004788",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/21/1559",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about satralizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console